Patent Infringement Special Report: Part I, The Most Pressing Case

OneMedPlace is publishing a special in-depth look into the state of patent infringement in drug manufacturing.

Read more »

No Shortage of Hopefuls in the Multibillion-Dollar Blood Thinner Business

Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.

Read more »

China Becoming Hot Spot for Western Pharma, Biotech Firms

Asian countries such as India and Japan have gained notoriety for their talented scientists and innovative contributions to the life sciences. Now, a new contender is emerging as a potential industry leader.

Read more »

AstraZeneca’s Heart Drug Beats Plavix in Phase III Study

Blood-thinning drug Plavix racks up over $8 billion in annual sales, but the blockbuster medication may have some new competition.

Read more »

More Good News for AstraZeneca

A new analysis of AstraZeneca’s cholesterol-lowering statin Crestor shows that the drug sharply reduces the risk of venous thromboembolism (VTE), a potentially fatal disorder in which blood clots can form in the legs and travel to the lungs.

Read more »

Two Studies Show Potential for Treating Drug-Resistant TB

Tuberculosis, or TB, is one of the world’s most widespread lethal diseases, killing someone every 20 seconds. An estimated one-third of the world’s population is infected with tuberculosis. Current medications for TB must be taken for six months, but many patients stop before they’ve completed the full course, which has caused drug-resistant strains of TB to develop in recent years. However, two new studies are showing promise in treating this highly infectious disease.

According to Science Daily, the Albert Einstein College of Medicine at Yeshiva University found that a combination of two FDA-approved antibiotics showed potential for treating drug-resistant TB. One of the drugs, clavulanate, inhibits a bacterial enzyme that normally protects TB bacteria from the other antibiotic (meropenem). Clinical trials of the combined treatment are scheduled to take place later this year in South Africa and South Korea.

Read more »